Advancements in natural and modern treatments for Alzheimer's disease in preclinical and early stages
DOI:
https://doi.org/10.69857/joapr.v14i2.1600Keywords:
Alzheimer's disease, Neuroprotection, Phytochemicals, Disease-modifying therapies, Integrative medicineAbstract
Background: Alzheimer's disease (AD), the most common cause of dementia, is characterized by memory loss, cognitive decline, and behavioral changes. Current monoclonal antibodies raise concerns about cost and safety, despite modest disease-modifying effects. Methodology: Evidence from preclinical research, clinical trials, and meta-analyses on integrative methods for managing AD is compiled in this narrative review. We assessed natural phytochemicals (from plants like Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, and Salvia officinalis), lifestyle modifications, and new technologies. With an emphasis on preclinical and early-stage AD data through 2025, standardized extracts such as EGb761 and saffron were given priority. Results: Certain plants' phytochemicals have anti-inflammatory, anti-amyloid, antioxidant, and neurotrophic properties that alter important AD pathways. Standardized extracts such as EGb761 and saffron have been shown in clinical trials to provide cognitive benefits comparable to those of prescription medications, with fewer side effects. Pharmacotherapy, natural modulators, stem cell therapy, AI-driven precision medicine, and other integrative strategies have shown promise in slowing disease progression. Discussion: Low bioavailability, formulation variability, and a lack of large-scale trials are some of the issues facing clinical translation. Natural remedies can complement modern treatments, particularly during the early stages of AD. Standardized formulations, sophisticated delivery methods, and thorough verification of synergistic strategies are essential for future success. Conclusion: Modern and natural therapies present promising options for managing AD at an early stage. Integrative care must be advanced through standardized formulations, enhanced delivery techniques, and robust clinical validation of synergistic approaches.
Downloads
References
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement, 14, 535–62 (2018) https://doi.org/10.1016/j.jalz.2018.02.018
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7, 280–92 (2011) https://doi.org/10.1016/j.jalz.2011.03.003
Mormino EC, Papp KV. Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease. J Alzheimers Dis, 64, S633–46 (2018) https://doi.org/10.3233/JAD-179928
Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Rapid decline in episodic memory in healthy older adults with high amyloid-β. J Alzheimers Dis, 33, 675–79 (2013) https://doi.org/10.3233/JAD-2012-121516
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement, 10, 844–52 (2014) https://doi.org/10.1016/j.jalz.2014.01.001
Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer's disease. Annu Rev Clin Psychol, 13, 369–96 (2017) https://doi.org/10.1146/annurev-clinpsy-032816-045136
van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement, 9, 481–87 (2013) https://doi.org/10.1016/j.jalz.2012.08.004
Schwarz C, Lange C, Benson GS, Horn N, Wurdack K, Lukas M. Severity of subjective cognitive complaints and worries in older adults are associated with cerebral amyloid-β load. Front Aging Neurosci, 13, 675583 (2021) https://doi.org/10.3389/fnagi.2021.675583
Salthouse TA. Selective review of cognitive aging. J Int Neuropsychol Soc, 16, 754–60 (2010) https://doi.org/10.1017/S1355617710000706
Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology, 78, 387–95 (2012) https://doi.org/10.1212/WNL.0b013e318245d295
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol, 71, 961–70 (2014) https://doi.org/10.1001/jamaneurol.2014.803
Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol, 11, 1006–12 (2012) https://doi.org/10.1016/S1474-4422(12)70191-6
Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr, 10, 14 (2010) https://doi.org/10.1186/1471-2318-10-14
Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med, 14, 707–13 (2008) https://doi.org/10.1089/acm.2008.0018
Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, et al. Withania somnifera reverses Alzheimer’s pathology. Proc Natl Acad Sci U S A, 109, 3510–15 (2012) https://doi.org/10.1073/pnas.1112209109
Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res, 2, 131–36 (2005) https://doi.org/10.2174/1567205053585882
Gray NE, Morré J, Kelley J, Maier CS, Stevens JF, Quinn JF, Soumyanath A. Caffeoylquinic acids in Centella asiatica protect against amyloid-β toxicity. J Alzheimers Dis, 40, 359–73 (2014) https://doi.org/10.3233/JAD-131913
Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. Eur J Neurol, 15, 865–68 (2008) https://doi.org/10.1111/j.1468-1331.2008.02157.x
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther, 28, 53–59 (2003) https://doi.org/10.1046/j.1365-2710.2003.00463.x
Rai KS, Murthy KD, Karanth KS, Rao MS. Clitoria ternatea root extract enhances acetylcholine content in rat hippocampus. Fitoterapia, 73, 685–89 (2002) https://doi.org/10.1016/S0367-326X(02)00249-6
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther, 35, 581–88 (2010) https://doi.org/10.1111/j.1365-2710.2009.01133.x
Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav, 72, 953–64 (2002) https://doi.org/10.1016/S0091-3057(02)00777-3
Biasibetti R, Tramontina AC, Costa AP, da Silva TM, Wartchow KM, Lunardi PS. Green tea (−)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav Brain Res, 236, 186–93 (2013) https://doi.org/10.1016/j.bbr.2012.08.039
Liu JY, Dai Y, He YX, Lin L. Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: a systematic review and meta-analysis. Front Pharmacol, 14, 1301102 (2024) https://doi.org/10.3389/fphar.2023.1301102
Hussain H, Ahmad S, Shah SWA, Ullah A, Ali N, Almehmadi M, et al. Attenuation of scopolamine-induced amnesia via cholinergic modulation in mice by synthetic curcumin analogs. Molecules, 27, 2468 (2022) https://doi.org/10.3390/molecules27082468
Saenghong N, Wattanathorn J, Muchimapura S, Tongun T, Piyavhatkul N, Banchonglikitkul C, Kajsongkram T. Zingiber officinale improves cognitive function of middle-aged healthy women. Evid Based Complement Alternat Med, 2012, 383062 (2012) https://doi.org/10.1155/2012/383062
Birks JS, Harvey RJ. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev, 9, CD001191 (2015) https://doi.org/10.1002/14651858.CD001191.pub4
Kumar A, Gupta V, Sharma S. Donepezil. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; (2025) https://www.ncbi.nlm.nih.gov/books/NBK513257/
McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev, 2, CD003154 (2006) https://doi.org/10.1002/14651858.CD003154.pub5
Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev, 4, CD001747 (2001) https://doi.org/10.1002/14651858.CD001747.pub2
Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci, 15, 1169499 (2023) https://doi.org/10.3389/fnagi.2023.1169499
U.S. Food and Drug Administration. FDA grants accelerated approval for Alzheimer’s drug (2021) https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only
Sneha Sri R, Pavithra T, Vinciya T, Santhosh Kumar V, Harikrishnan N, Begum RF, Ankul Singh S. Integrative approaches in Alzheimer’s disease: evaluating the potential of traditional, complementary, and integrative medicine (TCIM). Front Pharmacol, 16, 1561702 (2025) https://doi.org/10.3389/fphar.2025.1561702
Gregory SM, Parker B, Thompson PD. Physical activity, cognitive function, and brain health: what is the role of exercise training in the prevention of dementia? Brain Sci, 2(4), 684–708 (2012) https://doi.org/10.3390/brainsci2040684
Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr, 7, 889–904 (2016) https://doi.org/10.3945/an.116.012138
Khemka S, Reddy A, Garcia RI, Jacobs M, Reddy RP, Roghani AK, et al. Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases. Ageing Res Rev, 91, 102091 (2023) https://doi.org/10.1016/j.arr.2023.102091
Wang M, Huang W, Huang J, Luo Y, Huang N. Natural bioactive compounds from herbal medicine in Alzheimer’s disease: from the perspective of GSK-3β. Front Pharmacol, 16, 1497861 (2025) https://doi.org/10.3389/fphar.2025.1497861
Shoaib S, Ansari MA, Fatease AA, Safhi AY, Hani U, Jahan R, et al. Plant-derived bioactive compounds in the management of neurodegenerative disorders: challenges, future directions and molecular mechanisms involved in neuroprotection. Pharmaceutics, 15, 749 (2023) https://doi.org/10.3390/pharmaceutics15030749
Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol, 595, 197–212 (2007) https://doi.org/10.1007/978-0-387-46401-5_8
Bhat BA, Nabi S, Mudassar S, Dar NJ, Mustafa SS, Rashid R, et al. Natural therapeutics in aid of treating Alzheimer’s disease: a green gateway toward ending quest for treating neurological disorders. Front Neurosci, 16, 884345 (2022) https://doi.org/10.3389/fnins.2022.884345
Calderaro A, Patanè GT, Tellone E, Barreca D, Ficarra S, Misiti F, et al. The neuroprotective potentiality of flavonoids on Alzheimer’s disease. Int J Mol Sci, 23, 14835 (2022) https://doi.org/10.3390/ijms232314835
Anoop A, Singh PK, Jacob RS, Maji SK. CSF biomarkers for Alzheimer’s disease. Int J Alzheimers Dis, 2010, 606802 (2010) https://doi.org/10.4061/2010/606802
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol, 12, 207–16 (2013) https://doi.org/10.1016/S1474-4422(12)70291-0
Jipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov Disord, 33, 1287–97 (2018) https://doi.org/10.1002/mds.27376
Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, et al. CRISPR/Cas9 gene editing: new hope for Alzheimer's disease therapeutics. J Adv Res, 40, 207–21 (2022) https://doi.org/10.1016/j.jare.2021.07.001
Liu XY, Yang LP, Zhao L. Stem cell therapy for Alzheimer’s disease. World J Stem Cells, 12, 787–802 (2020) https://doi.org/10.4252/wjsc.v12.i8.787
Benster LL, Weissman CR, Stolz LA, Daskalakis ZJ, Appelbaum LG. Pre-clinical indications of brain stimulation treatments for non-affective psychiatric disorders: a status update. Transl Psychiatry, 13, 390 (2023) https://doi.org/10.1038/s41398-023-02673-2
Schork NJ. Artificial intelligence and personalized medicine. Cancer Treat Res, 178, 265–83 (2019) https://doi.org/10.1007/978-3-030-16391-4_11
Pais M, Pupi A, Sorbi S, Caraci F. Early diagnosis and treatment of Alzheier’s disease. Braz J Psychiatry, 42, 431–41 (2020) https://doi.org/10.1590/1516-4446-2019-0735
Published
How to Cite
Issue
Section
Copyright (c) 2026 Ronald Darwin C, Latha S
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
